Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on disease for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients lives. In animal health, Boeringer Ingelheim stands for advanced prevention. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical indsutry’s top 20 companies. Some 50.000 employees create value through innovation dailyfor the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17,5 billion euros, R&D expenditure of almost 3,2 billion euros, corresponded to 18,1 percent of net sales.